Siegel, R. L. et al. Cancer statistics, 2025. CA Cancer J. Clin. 75, 10–45 (2025).
Google Scholar
Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229–263 (2024).
Google Scholar
GBD 2023 Breast Cancer Collaborators The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 406, 1565–1586 (2025).
Google Scholar
GlobalSurg Collaborative and National Institute for Health Research Global Health Research Unit on Global Surgery Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries. Lancet 397, 387–397 (2021).
Google Scholar
Cortes, J. et al. Enhancing global access to cancer medicines. CA Cancer J. Clin. 70, 105–124 (2020).
Google Scholar
Chen, B. et al. Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions. Mol. Cancer 24, 279 (2025).
Google Scholar
Wang, R. et al. Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals. J. Hematol. Oncol. 18, 51 (2025).
Google Scholar
Deckers, J. et al. Engineering cytokine therapeutics. Nat. Rev. Bioeng. 1, 286–303 (2023).
Google Scholar
Fenis, A. et al. New immune cell engagers for cancer immunotherapy. Nat. Rev. Immunol. 24, 471–486 (2024).
Google Scholar
Bashor, C. J. et al. Engineering the next generation of cell-based therapeutics. Nat. Rev. Drug Discov. 21, 655–675 (2022).
Google Scholar
Lefrère, J. J. & Berche, P. [Doctor Brown-Sequard’s therapy]. Ann. Endocrinol. 71, 69–75 (2010).
Google Scholar
Thomas, E. D. et al. Supralethal whole body irradiation and isologous marrow transplantation in man. J. Clin. Invest. 38, 1709–1716 (1959).
Google Scholar
Rosenberg, S. A. et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313, 1485–1492 (1985).
Google Scholar
Eshhar, Z., Waks, T., Gross, G. & Schindler, D. G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA 90, 720–724 (1993).
Google Scholar
Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439–448 (2018).
Google Scholar
Zugasti, I. et al. CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct. Target. Ther. 10, 210 (2025).
Google Scholar
Liao, Q. et al. PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo. Biomark. Res. 8, 57 (2020).
Google Scholar
Nguyen, N. T. et al. Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety. Nat. Nanotechnol. 16, 1424–1434 (2021).
Google Scholar
Benthani, F., Upadhaya, S. & Zhou, A. Cancer cell therapies: global clinical trial trends and emerging directions. Nat. Rev. Drug Discov. 24, 898–899 (2025).
Google Scholar
June, C. H., Blazar, B. R. & Riley, J. L. Engineering lymphocyte subsets: tools, trials and tribulations. Nat. Rev. Immunol. 9, 704–716 (2009).
Google Scholar
Jiang, N. et al. Recent advances in universal chimeric antigen receptor T cell therapy. J. Hematol. Oncol. 18, 82 (2025).
Google Scholar
June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64–73 (2018).
Google Scholar
Sadelain, M., Rivière, I. & Riddell, S. Therapeutic T cell engineering. Nature 545, 423–431 (2017).
Google Scholar
Uslu, U., Castelli, S. & June, C. H. CAR T cell combination therapies to treat cancer. Cancer Cell 42, 1319–1325 (2024).
Google Scholar
Maus, M. V., Grupp, S. A., Porter, D. L. & June, C. H. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123, 2625–2635 (2014).
Google Scholar
Elazar, A. et al. De novo-designed transmembrane domains tune engineered receptor functions. eLife 11, e75660 (2022).
Google Scholar
Guedan, S., Ruella, M. & June, C. H. Emerging cellular therapies for cancer. Annu. Rev. Immunol. 37, 145–171 (2019).
Google Scholar
Cappell, K. M. & Kochenderfer, J. N. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. Nat. Rev. Clin. Oncol. 18, 715–727 (2021).
Google Scholar
Patel, K. K. et al. From concept to cure: the evolution of CAR-T cell therapy. Mol. Ther. 33, 2123–2140 (2025).
Google Scholar
Kuwana, Y. et al. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem. Biophys. Res. Commun. 149, 960–968 (1987).
Google Scholar
Irving, B. A. & Weiss, A. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 64, 891–901 (1991).
Google Scholar
Sadelain, M., Rivière, I. & Brentjens, R. Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer 3, 35–45 (2003).
Google Scholar
Sadelain, M., Brentjens, R. & Rivière, I. The basic principles of chimeric antigen receptor design. Cancer Discov. 3, 388–398 (2013).
Google Scholar
Chen, L. & Flies, D. B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13, 227–242 (2013).
Google Scholar
Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-CELL Lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017).
Google Scholar
Porter, D. L. et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725–733 (2011).
Google Scholar
Collinson-Pautz, M. R. et al. Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies. Leukemia 33, 2195–2207 (2019).
Google Scholar
Verma, M. et al. The next-generation CAR-T therapy landscape. Nat. Rev. Drug Discov. 22, 776–777 (2023).
Google Scholar
Hong, M., Clubb, J. D. & Chen, Y. Y. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell 38, 473–488 (2020).
Google Scholar
Kagoya, Y. et al. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat. Med. 24, 352–359 (2018).
Google Scholar
Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359–371 (2023).
Google Scholar
Melenhorst, J. J. et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature 602, 503–509 (2022).
Google Scholar
Qin, H. et al. Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects. J. Hematol. Oncol. 18, 62 (2025).
Google Scholar
Saez-Ibañez, A. R. et al. The changing landscape of cancer cell therapies: clinical trials and real-world data. Nat. Rev. Drug Discov. 23, 736–737 (2024).
Google Scholar
Rosenbaum, L. Tragedy, perseverance, and chance – the story of CAR-T therapy. N. Engl. J. Med. 377, 1313–1315 (2017).
Google Scholar
Frank, M. J. et al. CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study. Lancet 404, 353–363 (2024).
Google Scholar
Roloff, G. W. et al. Outcomes after brexucabtagene autoleucel administered as a standard therapy for adults with relapsed/refractory B-Cell ALL. J. Clin. Oncol. 43, 558–566 (2025).
Google Scholar
Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).
Google Scholar
Wang, T. et al. Coadministration of CD19- and CD22-directed chimeric antigen receptor T-cell therapy in childhood B-cell acute lymphoblastic leukemia: a single-arm, multicenter, phase II trial. J. Clin. Oncol. 41, 1670–1683 (2023).
Google Scholar
Wang, M. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 382, 1331–1342 (2020).
Google Scholar
Pasquini, M. C. et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 4, 5414–5424 (2020).
Google Scholar
Locke, F. L. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N. Engl. J. Med. 386, 640–654 (2022).
Google Scholar
Roddie, C. et al. Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia. N. Engl. J. Med. 391, 2219–2230 (2024).
Google Scholar
Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705–716 (2021).
Google Scholar
Lin, Y. et al. CARTITUDE-1 final results: phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma. J. Clin. Oncol. 41, 8009 (2023).
Google Scholar
Jagannath, S. et al. Long-term (≥5-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed/refractory multiple myeloma. J. Clin. Oncol. 43, 2766–2771 (2025).
Google Scholar
Rodríguez Otero, P. et al. Idecabtagene vicleucel (ide-cel) versus standard (std) regimens in patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): updated analysis from KarMMa-3. Blood 142, 1028 (2023).
Google Scholar
Sidana, S. et al. Ciltacabtagene autoleucel (cilta-cel) vs standard of care (SOC) in patients (pts) with relapsed/refractory multiple myeloma (MM): CARTITUDE-4 survival subgroup analyses. J. Clin. Oncol. 43, 7539 (2025).
Google Scholar
Freiwan, A. et al. Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies. Blood 140, 2684–2696 (2022).
Google Scholar
Sallman, D. A. et al. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. Lancet Haematol. 10, e191–e202 (2023).
Google Scholar
Wermke, M. et al. Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML. Blood 137, 3145–3148 (2021).
Google Scholar
Jetani, H. et al. Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia. Blood 138, 1830–1842 (2021).
Google Scholar
Qi, C. et al. Safety and efficacy of CT041 in patients with refractory metastatic pancreatic cancer: a pooled analysis of two early-phase trials. J. Clin. Oncol. 42, 2565–2577 (2024).
Google Scholar
Brown, C. E. et al. Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat. Med. 30, 1001–1012 (2024).
Google Scholar
Monje, M. et al. Intravenous and intracranial GD2-CAR T cells for H3K27M(+) diffuse midline gliomas. Nature 637, 708–715 (2025).
Google Scholar
Qi, C. et al. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician’s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. Lancet 405, 2049–2060 (2025).
Google Scholar
Carstens, E. J. et al. Modeling and addressing on-target/off-tumor toxicity of claudin 18.2 targeted immunotherapies. Nat. Commun. 16, 9651 (2025).
Google Scholar
Zang, P. D., Angeles, A. & Pal, S. K. CD70: an emerging anticancer target in renal cell carcinoma and beyond. Annu. Rev. Med. 76, 257–266 (2025).
Google Scholar
Pal, S. K. et al. CD70-targeted allogeneic CAR T-cell therapy for advanced clear cell renal cell carcinoma. Cancer Discov. 14, 1176–1189 (2024).
Google Scholar
Srour, S. A. et al. ALLO-316 in advanced clear cell renal cell carcinoma (ccRCC): Updated results from the phase 1 TRAVERSE study. J. Clin. Oncol. 43, 4508 (2025).
Google Scholar
Zhang, Q. et al. Phase I study of C-CAR031, a GPC3-specific TGFβRIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC). J. Clin. Oncol. 42, 4019 (2024).
Google Scholar
Shi, Y. et al. Combined local therapy and CAR-GPC3 T-cell therapy in advanced hepatocellular carcinoma: a proof-of-concept treatment strategy. Cancer Commun. 43, 1064–1068 (2023).
Google Scholar
Brown, C. E. et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 375, 2561–2569 (2016).
Google Scholar
Bagley, S. J. et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results. Nat. Med. 30, 1320–1329 (2024).
Google Scholar
Majzner, R. G. et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603, 934–941 (2022).
Google Scholar
Wei, S. et al. Hypoxia-responsive CEA CAR-T cells therapy for relapsed or refractory non-small cell lung cancer: A single-arm, open-label, phase I trial. J. Clin. Oncol. 43, 8517 (2025).
Google Scholar
Flugel, C. L. et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat. Rev. Clin. Oncol. 20, 49–62 (2023).
Google Scholar
Smith, C. C. et al. Alternative tumour-specific antigens. Nat. Rev. Cancer 19, 465–478 (2019).
Google Scholar
Azeez, S. S. et al. Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives. Mol. Cancer 24, 191 (2025).
Google Scholar
Haas, A. R. et al. Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells. Mol. Ther. 31, 2309–2325 (2023).
Google Scholar
Li, J. et al. Optimizing CAR T cell therapy for solid tumours: a clinical perspective. Nat. Rev. Clin. Oncol. 22, 953–968 (2025).
Google Scholar
Horna, P., Nowakowski, G., Endell, J. & Boxhammer, R. Comparative assessment of surface CD19 and CD20 expression on B-cell lymphomas from clinical biopsies: implications for targeted therapies. Blood 134, 5345 (2019).
Google Scholar
Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. Nat. Med. 30, 2224–2234 (2024).
Google Scholar
Hirabayashi, K. et al. Dual targeting CAR-T cells with optimal costimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nat. Cancer 2, 904–918 (2021).
Google Scholar
Shah, N. N. & Fry, T. J. Mechanisms of resistance to CAR T cell therapy. Nat. Rev. Clin. Oncol. 16, 372–385 (2019).
Google Scholar
O’Rourke, D. M. et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med. 9, eaaa0984 (2017).
Google Scholar
Qi, C. et al. (68)Ga-NC-BCH whole-body PET imaging rapidly targets Claudin18.2 in lesions in gastrointestinal cancer patients. J. Nucl. Med. 65, 856–863 (2024).
Google Scholar
Nie, Y. Breaking barriers: the emerging promise of CAR-T cell therapy in solid tumors. Holist. Integr. Oncol. 4, 70 (2025).
Google Scholar
Tousley, A. M. et al. Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature 615, 507–516 (2023).
Google Scholar
James, S. E. et al. Leucine zipper-based immunomagnetic purification of CAR T cells displaying multiple receptors. Nat. Biomed. Eng. 8, 1592–1614 (2024).
Google Scholar
Li, Y. R., Zhu, Y., Halladay, T. & Yang, L. In vivo CAR engineering for immunotherapy. Nat. Rev. Immunol. 25, 725–744 (2025).
Google Scholar
Bot, A. et al. In vivo chimeric antigen receptor (CAR)-T cell therapy. Nat. Rev. Drug Discov. 25, 116–137 (2026).
Google Scholar
Chen, N. et al. Chimeric antigen receptor T cells targeting CD19 and GCC in metastatic colorectal cancer: a nonrandomized clinical trial. JAMA Oncol. 10, 1532–1536 (2024).
Google Scholar
Yagel, G. et al. Tumor-antigen-independent targeting of solid tumors by armored macrophage-directed anti-TREM2 CAR T cells. Cancer Cell 44, 519–533 (2026).
Google Scholar
Liu, L. et al. Engineering sonogenetic EchoBack-CAR T cells. Cell 188, 2621–2636.e2620 (2025).
Google Scholar
Chen, A. X. Y. et al. Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery. Nature 644, 241–251 (2025).
Google Scholar
Su, J. et al. Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies. J. Hematol. Oncol. 18, 90 (2025).
Google Scholar
Adachi, K. et al. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat. Biotechnol. 36, 346–351 (2018).
Google Scholar
Nakajima, T. E. et al. Updated results from first-in-human phase 1 dose-escalation trial of TAK-102, a GPC3-targeted armored CAR T cells, in patients with advanced solid tumors. J. Clin. Oncol. 42, 2543 (2024).
Google Scholar
Katz, S. C. et al. HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases. Cancer Gene Ther. 27, 341–355 (2020).
Google Scholar
Katz, S. C. et al. HITM-SURE: hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery. J. Immunother. Cancer 8, e001097 (2020).
Google Scholar
Abou-El-Enein, M. et al. Scalable manufacturing of CAR T cells for cancer immunotherapy. Blood Cancer Discov. 2, 408–422 (2021).
Google Scholar
Elsallab, M. & Maus, M. V. Expanding access to CAR T cell therapies through local manufacturing. Nat. Biotechnol. 41, 1698–1708 (2023).
Google Scholar
Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11, 69 (2021).
Google Scholar
Amini, L. et al. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat. Rev. Clin. Oncol. 19, 342–355 (2022).
Google Scholar
Labanieh, L. & Mackall, C. L. CAR immune cells: design principles, resistance and the next generation. Nature 614, 635–648 (2023).
Google Scholar
Agarwal, S. et al. In vivo generation of CAR T cells selectively in human CD4(+) lymphocytes. Mol. Ther. 28, 1783–1794 (2020).
Google Scholar
Ho, N. et al. In vivo generation of CAR T cells in the presence of human myeloid cells. Mol. Ther. Methods Clin. Dev. 26, 144–156 (2022).
Google Scholar
Tombácz, I. et al. Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs. Mol. Ther. 29, 3293–3304 (2021).
Google Scholar
Billingsley, M. M. et al. In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism. Small 20, e2304378 (2024).
Google Scholar
Kheirolomoom, A. et al. In situ T-cell transfection by anti-CD3-conjugated lipid nanoparticles leads to T-cell activation, migration, and phenotypic shift. Biomaterials 281, 121339 (2022).
Google Scholar
Zhou, J. E. et al. Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo. J. Control Release 350, 298–307 (2022).
Google Scholar
Huckaby, J. T. et al. Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells. J. Immunother. Cancer 9, e002737 (2021).
Google Scholar
Michels, K. R. et al. Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering. J. Immunother. Cancer 11, e006292 (2023).
Google Scholar
Charitidis, F. T. et al. CAR gene delivery by T-cell targeted lentiviral vectors is enhanced by rapamycin induced reduction of antiviral mechanisms. Adv. Sci. 10, 2302992 (2023).
Google Scholar
Andorko, J. I. et al. Targeted in vivo delivery of genetic medicines utilizing an engineered lentiviral vector platform results in CAR T and NK cell generation. Mol. Ther. 33, 4937–4952 (2025).
Google Scholar
Garcia, J. R. A phase I, multicenter, open-label study of UB-VV111 in combination with rapamycin in relapsed/refractory CD19+ B-cell malignancies. J. Clin. Oncol. 43, TPS2681 (2025).
Google Scholar
Hunter, T. L. et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science 388, 1311–1317 (2025).
Google Scholar
Lemgart, V. et al. In vitro and in vivo activity of a lipid nanoparticle system for the in vivo generation of CAR T cells. Blood 144, 3421 (2024).
Google Scholar
Bui, T. A. et al. Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment. EBioMedicine 106, 105266 (2024).
Google Scholar
Xu, J. et al. In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma. Lancet 406, 228–231 (2025).
Google Scholar
Liu, Y. et al. In situ MUC1-specific CAR engineering of tumor-supportive macrophages stimulates tumoricidal immunity against pancreatic adenocarcinoma. Nano Today 49, 101805 (2023).
Google Scholar
Yang, Z. et al. Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy. J. Control Release 360, 718–733 (2023).
Google Scholar
Mukalel, A. J. et al. Oxidized mRNA lipid nanoparticles for in situ chimeric antigen receptor monocyte engineering. Adv. Funct. Mater. 34, 2312038 (2024).
Google Scholar
Gao, L. et al. Convection-enhanced delivery of nanoencapsulated gene locoregionally yielding ErbB2/Her2-specific CAR-macrophages for brainstem glioma immunotherapy. J. Nanobiotechnology. 21, 56 (2023).
Google Scholar
Chen, C. et al. Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy. Sci. Transl. Med. 14, eabn1128 (2022).
Google Scholar
van der Merwe, P. A. & Dushek, O. Mechanisms for T cell receptor triggering. Nat. Rev. Immunol. 11, 47–55 (2011).
Google Scholar
Baulu, E., Gardet, C., Chuvin, N. & Depil, S. TCR-engineered T cell therapy in solid tumors: State of the art and perspectives. Sci. Adv. 9, eadf3700 (2023).
Google Scholar
Blüthmann, H. et al. T-cell-specific deletion of T-cell receptor transgenes allows functional rearrangement of endogenous alpha- and beta-genes. Nature 334, 156–159 (1988).
Google Scholar
Call, M. E., Pyrdol, J., Wiedmann, M. & Wucherpfennig, K. W. The organizing principle in the formation of the T cell receptor-CD3 complex. Cell 111, 967–979 (2002).
Google Scholar
Courtney, A. H., Lo, W. L. & Weiss, A. TCR signaling: mechanisms of initiation and propagation. Trends Biochem. Sci. 43, 108–123 (2018).
Google Scholar
Hwang, J. R., Byeon, Y., Kim, D. & Park, S. G. Recent insights of T cell receptor-mediated signaling pathways for T cell activation and development. Exp. Mol. Med. 52, 750–761 (2020).
Google Scholar
Chandran, S. S. & Klebanoff, C. A. T cell receptor-based cancer immunotherapy: emerging efficacy and pathways of resistance. Immunol. Rev. 290, 127–147 (2019).
Google Scholar
Zhang, Y., Liu, Z., Wei, W. & Li, Y. TCR engineered T cells for solid tumor immunotherapy. Exp. Hematol. Oncol. 11, 38 (2022).
Google Scholar
Anderson, G. S. F. & Chapman, M. A. T cell-redirecting therapies in hematological malignancies: current developments and novel strategies for improved targeting. Mol. Ther. 32, 2856–2891 (2024).
Google Scholar
Yun, K., Siegler, E. L. & Kenderian, S. S. Who wins the combat, CAR or TCR? Leukemia 37, 1953–1962 (2023).
Google Scholar
Sykulev, Y. et al. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 4, 565–571 (1996).
Google Scholar
Davenport, A. J. et al. Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity. Proc. Natl. Acad. Sci. USA 115, E2068–e2076 (2018).
Google Scholar
Li, X. et al. Lytic IFNγ is stored in cytotoxic granules and coreleased with granzyme B to mediate cytotoxic T lymphocyte killing. Cell Mol. Immunol. 23, 400–416 (2026).
Google Scholar
Clay, T. M. et al. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol. 163, 507–513 (1999).
Google Scholar
Morgan, R. A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126–129 (2006).
Google Scholar
Croce, G. et al. Phage display enables machine learning discovery of cancer antigen-specific TCRs. Sci. Adv. 11, eads5589 (2025).
Google Scholar
Kueberuwa, G. et al. CCR7(+) selected gene-modified T cells maintain a central memory phenotype and display enhanced persistence in peripheral blood in vivo. J. Immunother. Cancer 5, 14 (2017).
Google Scholar
Nathan, P. et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N. Engl. J. Med. 385, 1196–1206 (2021).
Google Scholar
Mazziotta, F. et al. A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence. Nat. Commun. 16, 5214 (2025).
Google Scholar
van Amerongen, R. A. et al. WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma. J. Immunother. Cancer 10, e004409 (2022).
Google Scholar
Tawara, I. et al. Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS. Blood 130, 1985–1994 (2017).
Google Scholar
Foldvari, Z. et al. Targeting the roots of myeloid malignancies with T cell receptors. Nat. Rev. Cancer 25, 965–985 (2025).
Google Scholar
Chapuis, A. G. et al. T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. Nat. Med. 25, 1064–1072 (2019).
Google Scholar
Robbins, P. F. et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917–924 (2011).
Google Scholar
Robbins, P. F. et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1–reactive T-cell receptor: long-term follow-up and correlates with response. Clin. Cancer Res. 21, 1019–1027 (2015).
Google Scholar
Pan, Q. et al. Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A∗02:01 patients with advanced soft tissue sarcoma. Cell Rep. Med. 4, 101133 (2023).
Google Scholar
Barnett, K. K. et al. FDA approval summary: afamitresgene autoleucel for adults with HLA-restricted, MAGE-A4–positive unresectable or metastatic synovial sarcoma after prior chemotherapy. Clin. Cancer Res. 31, 3112–3117 (2025).
Google Scholar
D’Angelo, S. P. et al. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet 403, 1460–1471 (2024).
Google Scholar
Wermke, M. et al. Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial. Nat. Med. 31, 2365–2374 (2025).
Google Scholar
Nagarsheth, N. B. et al. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nat. Med. 27, 419–425 (2021).
Google Scholar
Jia, Q. et al. TCR-T cells armored with immune checkpoint blockade in EBV-positive nasopharyngeal carcinoma: The first-in-human phase 1/2 trial. J. Clin. Oncol. 41, 6047 (2023).
Google Scholar
Eggebø, M. S. et al. TCR-engineered T cells targeting a shared β-catenin mutation eradicate solid tumors. Nat. Immunol. 26, 1726–1736 (2025).
Google Scholar
Leidner, R. et al. Neoantigen T-cell receptor gene therapy in pancreatic cancer. N. Engl. J. Med. 386, 2112–2119 (2022).
Google Scholar
Parkhurst, M. et al. Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results. Nat. Med. 30, 2586–2595 (2024).
Google Scholar
Heemskerk, M. H. et al. Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood 109, 235–243 (2007).
Google Scholar
Topalian, S. L. et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J. Clin. Oncol. 6, 839–853 (1988).
Google Scholar
Hudson, W. H. & Wieland, A. Technology meets TILs: deciphering T cell function in the -omics era. Cancer Cell 41, 41–57 (2023).
Google Scholar
Levin, N. et al. Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes. J. Immunother. Cancer 12, e008645 (2024).
Google Scholar
Rosenberg, S. A. et al. Gene transfer into humans–immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 323, 570–578 (1990).
Google Scholar
Eberlein, T. J., Rosenstein, M. & Rosenberg, S. A. Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. J. Exp. Med. 156, 385–397 (1982).
Google Scholar
Rosenberg, S. A. et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319, 1676–1680 (1988).
Google Scholar
Besser, M. J. et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 16, 2646–2655 (2010).
Google Scholar
Okamura, K. et al. Lymphocytes in tumor-draining lymph nodes co-cultured with autologous tumor cells for adoptive cell therapy. J. Transl. Med. 20, 241 (2022).
Google Scholar
Schumacher, T. N., Scheper, W. & Kvistborg, P. Cancer neoantigens. Annu. Rev. Immunol. 37, 173–200 (2019).
Google Scholar
Zacharakis, N. et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat. Med. 24, 724–730 (2018).
Google Scholar
Tran, E. et al. T-cell transfer therapy targeting mutant KRAS in cancer. N. Engl. J. Med. 375, 2255–2262 (2016).
Google Scholar
Lowery, F. J. et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science 375, 877–884 (2022).
Google Scholar
Rosenberg, S. A. & Dudley, M. E. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc. Natl. Acad. Sci. USA 101, 14639–14645 (2004).
Google Scholar
Hu, W., Bian, Y. & Ji, H. TIL therapy in lung cancer: current progress and perspectives. Adv. Sci. 11, e2409356 (2024).
Google Scholar
Hong, H. et al. Clinical trial landscape for TIL therapy: emerging insights and future directions in oncology. J. Transl. Med. 22, 1008 (2024).
Google Scholar
Dafni, U. et al. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Ann. Oncol. 30, 1902–1913 (2019).
Google Scholar
Rosenberg, S. A. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550–4557 (2011).
Google Scholar
Klobuch, S., Seijkens, T. T. P., Schumacher, T. N. & Haanen, J. Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma. Nat. Rev. Clin. Oncol. 21, 173–184 (2024).
Google Scholar
Jazaeri, A. A. et al. Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma. J. Clin. Oncol. 37, 2538 (2019).
Google Scholar
Creelan, B. et al. Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non-small cell lung cancer (NSCLC): a phase I trial. Cancer Res. 80, CT056 (2020).
Google Scholar
Plaugher, D. R. et al. Therapeutic potential of tumor-infiltrating lymphocytes in non-small cell lung cancer. Cancer Lett. 605, 217281 (2024).
Google Scholar
Lowery, F. J. et al. Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial. Nat. Med. 31, 1994–2003 (2025).
Google Scholar
Xia, T. et al. Autologous tumor-infiltrating lymphocyte infusion plus anti-programmed cell death protein 1 therapy to cure advanced hepatocellular carcinoma following palliative hepatectomy. Liver Cancer 14, 497–505 (2025).
Google Scholar
Betof Warner, A. et al. Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy. J. Immunother. Cancer 12, e008735 (2024).
Google Scholar
Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546–1558 (2013).
Google Scholar
Dudley, M. E. et al. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J. Clin. Oncol. 31, 2152–2159 (2013).
Google Scholar
Arias-Badia, M., Chang, R. & Fong, L. γδ T cells as critical anti-tumor immune effectors. Nat. Cancer 5, 1145–1157 (2024).
Google Scholar
Silva-Santos, B., Mensurado, S. & Coffelt, S. B. γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer. Nat. Rev. Cancer 19, 392–404 (2019).
Google Scholar
Hayday, A., Dechanet-Merville, J., Rossjohn, J. & Silva-Santos, B. Cancer immunotherapy by γδ T cells. Science 386, eabq7248 (2024).
Google Scholar
Mensurado, S., Blanco-Domínguez, R. & Silva-Santos, B. The emerging roles of γδ T cells in cancer immunotherapy. Nat. Rev. Clin. Oncol. 20, 178–191 (2023).
Google Scholar
Silva-Santos, B., Serre, K. & Norell, H. γδ T cells in cancer. Nat. Rev. Immunol. 15, 683–691 (2015).
Google Scholar
Deseke, M. & Prinz, I. Ligand recognition by the γδ TCR and discrimination between homeostasis and stress conditions. Cell Mol. Immunol. 17, 914–924 (2020).
Google Scholar
Kabelitz, D. et al. Cancer immunotherapy with γδ T cells: many paths ahead of us. Cell Mol. Immunol. 17, 925–939 (2020).
Google Scholar
Sebestyen, Z. et al. Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies. Nat. Rev. Drug Discov. 19, 169–184 (2020).
Google Scholar
Neelapu, S. S. et al. A phase 1 safety and efficacy study of ADI-001 Anti-CD20 CAR-engineered allogeneic gamma delta (γδ) T cells in adults with B cell malignancies, in monotherapy and combination with IL-2. Blood 138, 2834 (2021).
Google Scholar
Alnaggar, M. et al. Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma. J. Immunother. Cancer 7, 36 (2019).
Google Scholar
Mirzaei, H. R. et al. Prospects for chimeric antigen receptor (CAR) γδ T cells: a potential game changer for adoptive T cell cancer immunotherapy. Cancer Lett. 380, 413–423 (2016).
Google Scholar
Wawrzyniecka, P. A. et al. Chimeric antigen receptor T cells for gamma-delta T cell malignancies. Leukemia 36, 577–579 (2022).
Google Scholar
Costa, G. P., Mensurado, S. & Silva-Santos, B. Therapeutic avenues for γδ T cells in cancer. J. Immunother. Cancer 11, e007955 (2023).
Google Scholar
Wilhelm, M. et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 102, 200–206 (2003).
Google Scholar
Van Acker, H. H. et al. Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells. J. Hematol. Oncol. 9, 101 (2016).
Google Scholar
Godder, K. T. et al. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant. 39, 751–757 (2007).
Google Scholar
Xu, Y. et al. Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer. Cell Mol. Immunol. 18, 427–439 (2021).
Google Scholar
Bruni, E. et al. Intrahepatic CD69(+)Vδ1 T cells re-circulate in the blood of patients with metastatic colorectal cancer and limit tumor progression. J. Immunother. Cancer 10, e004579 (2022).
Google Scholar
Sánchez Martínez, D. et al. Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia. J. Immunother. Cancer 10, e005400 (2022).
Google Scholar
Di Lorenzo, B. et al. Broad cytotoxic targeting of acute myeloid leukemia by polyclonal Delta One T cells. Cancer Immunol. Res. 7, 552–558 (2019).
Google Scholar
Tarannum, M. et al. Engineering innate immune cells for cancer immunotherapy. Nat. Biotechnol. 43, 516–533 (2025).
Google Scholar
Li, Z. et al. Comparative efficacy and safety of PSCA CAR-engineered Vδ1 γδ T cells for immunotherapy of pancreatic cancer. J. Immunother. Cancer 13, e011890 (2025).
Google Scholar
Zhu, Z. et al. mRNA-engineered CD5-CAR-γδT(CD5-) cells for the immunotherapy of T-cell acute lymphoblastic leukemia. Adv. Sci. 11, e2400024 (2024).
Google Scholar
Neelapu, S. S. et al. A phase 1 study of ADI-001: Anti-CD20 CAR-engineered allogeneic gamma delta (γδ) T cells in adults with B-cell malignancies. J. Clin. Oncol. 40, 7509 (2022).
Google Scholar
Makkouk, A. et al. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. J. Immunother. Cancer 9, e003441 (2021).
Google Scholar
Nishimoto, K. P. et al. ADI-270: an armored allogeneic gamma delta T cell therapy designed to target CD70-expressing solid and hematologic malignancies. J. Immunother. Cancer 13, e011704 (2025).
Google Scholar
Ang, W. X. et al. Electroporation of NKG2D RNA CAR improves Vγ9Vδ2 T cell responses against human solid tumor xenografts. Mol. Ther. Oncolytics 17, 421–430 (2020).
Google Scholar
Chen, L. et al. Chemical engineering of γδ T cells with cancer cell-targeting antibodies for enhanced tumor immunotherapy. Natl. Sci. Rev. 12, nwaf256 (2025).
Google Scholar
De Gassart, A. et al. Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell-mediated antitumor immune response. Sci. Transl. Med. 13, eabj0835 (2021).
Google Scholar
Garciaz, S. et al. Activation of γ9δ2 T cells by ICT01 as a novel immunotherapeutic approach for relapsed/refractory hematologic cancers (EVICTION trial). Ann. Oncol. 34, S543 (2023).
Google Scholar
Rigau, M. et al. Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells. Science 367, eaay5516 (2020).
Google Scholar
Mehra, N. et al. Early dose escalation of LAVA-1207, a novel bispecific gamma-delta T-cell engager (Gammabody), in patients with metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 41, 153 (2023).
Google Scholar
Huang, S. W. et al. BiTE-secreting CAR-γδT as a dual targeting strategy for the treatment of solid tumors. Adv. Sci. 10, e2206856 (2023).
Google Scholar
Lameris, R. et al. A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies. Cell Rep. Med. 4, 100961 (2023).
Google Scholar
van Diest, E. et al. Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds. J. Immunother. Cancer 9, e003850 (2021).
Google Scholar
Agbuduwe, C., Maher, J. & Anderson, J. Harnessing the immunotherapeutic potentials of gamma delta T cells against hematological malignancies. Hemasphere 9, e70182 (2025).
Google Scholar
Rao, A. et al. Gamma delta T cells in acute myeloid leukemia: biology and emerging therapeutic strategies. J. Immunother. Cancer 12, e007981 (2024).
Google Scholar
Alishah, K. et al. CRISPR/Cas9-mediated TGFβRII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro. J. Transl. Med. 19, 482 (2021).
Google Scholar
Vivier, E. et al. Innate or adaptive immunity? The example of natural killer cells. Science 331, 44–49 (2011).
Google Scholar
Vivier, E. et al. Innate lymphoid cells: 10 years on. Cell 174, 1054–1066 (2018).
Google Scholar
Vivier, E. et al. Functions of natural killer cells. Nat. Immunol. 9, 503–510 (2008).
Google Scholar
Maskalenko, N. A., Zhigarev, D. & Campbell, K. S. Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders. Nat. Rev. Drug Discov. 21, 559–577 (2022).
Google Scholar
Böttcher, J. P. et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell 172, 1022–1037.e1014 (2018).
Google Scholar
Barry, K. C. et al. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat. Med. 24, 1178–1191 (2018).
Google Scholar
Hatjiharissi, E. et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood 110, 2561–2564 (2007).
Google Scholar
Campbell, K. S. & Hasegawa, J. Natural killer cell biology: an update and future directions. J. Allergy Clin. Immunol. 132, 536–544 (2013).
Google Scholar
Zitti, B. & Bryceson, Y. T. Natural killer cells in inflammation and autoimmunity. Cytokine Growth Factor Rev. 42, 37–46 (2018).
Google Scholar
Shen, Z. et al. Adjusting the scope of natural killer cells in cancer therapy. Cell Mol. Immunol. 22, 699–711 (2025).
Google Scholar
Courtney, A. N., Tian, G. & Metelitsa, L. S. Natural killer T cells and other innate-like T lymphocytes as emerging platforms for allogeneic cancer cell therapy. Blood 141, 869–876 (2023).
Google Scholar
Parkhurst, M. R., Riley, J. P., Dudley, M. E. & Rosenberg, S. A. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin. Cancer Res. 17, 6287–6297 (2011).
Google Scholar
Vivier, E. et al. Natural killer cell therapies. Nature 626, 727–736 (2024).
Google Scholar
Ruggeri, L. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295, 2097–2100 (2002).
Google Scholar
Khani-Eshratabadi, M. et al. Potential therapeutic roles of natural killer cells in acute myeloid leukemia: a systematic review study. Clin. Exp. Med. 25, 233 (2025).
Google Scholar
Miller, J. S. et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105, 3051–3057 (2005).
Google Scholar
Shi, J. et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br. J. Haematol. 143, 641–653 (2008).
Google Scholar
Bajel, A. et al. First-in-human study of the CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia or high risk-myelodysplasia: updated safety, efficacy, pharmacokinetics and pharmacodynamics. Blood 142, 3474 (2023).
Google Scholar
Nieto, Y. et al. Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial. Nat. Med. 31, 1987–1993 (2025).
Google Scholar
Bae, W. K. et al. A phase I study of locoregional high-dose autologous natural killer cell therapy with hepatic arterial infusion chemotherapy in patients with locally advanced hepatocellular carcinoma. Front. Immunol. 13, 879452 (2022).
Google Scholar
Hong, G. et al. Effect of autologous NK cell immunotherapy on advanced lung adenocarcinoma with EGFR mutations. Precis Clin. Med. 2, 235–245 (2019).
Google Scholar
Asl, N. S. et al. Intra-lesion injection of activated natural killer (NK) cells in recurrent malignant brain tumors. Int Immunopharmacol. 120, 110345 (2023).
Google Scholar
Zhou, J. et al. Research status of colorectal cancer treatment based on natural killer cell immunotherapy. Oncol. Transl. Med. 11, 271–281 (2025).
Google Scholar
McErlean, E. M. & McCarthy, H. O. Non-viral approaches in CAR-NK cell engineering: connecting natural killer cell biology and gene delivery. J. Nanobiotechnology. 22, 552 (2024).
Google Scholar
Xie, G. et al. CAR-NK cells: A promising cellular immunotherapy for cancer. EBioMedicine 59, 102975 (2020).
Google Scholar
Laskowski, T. J., Biederstädt, A. & Rezvani, K. Natural killer cells in antitumour adoptive cell immunotherapy. Nat. Rev. Cancer 22, 557–575 (2022).
Google Scholar
Marin, D. et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1/2 trial. Nat. Med. 30, 772–784 (2024).
Google Scholar
Park, H. et al. Efficacy and safety of natural killer cell therapy in patients with solid tumors: a systematic review and meta-analysis. Front. Immunol. 15, 1454427 (2024).
Google Scholar
Maalej, K. M. et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol. Cancer 22, 20 (2023).
Google Scholar
Fang, F. et al. Advances in NK cell production. Cell Mol. Immunol. 19, 460–481 (2022).
Google Scholar
Ghobadi, A. et al. Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. Lancet 405, 127–136 (2025).
Google Scholar
Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545–553 (2020).
Google Scholar
Lei, W. et al. Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B-cell lymphoma: a phase 1 trial. Nat. Cancer 6, 786–800 (2025).
Google Scholar
Huang, R. et al. Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed/refractory AML: preclinical evaluation and phase I trial. Exp. Hematol. Oncol. 14, 1 (2025).
Google Scholar
Sauter, C. S. et al. A phase 1 study of NKX101, a chimeric antigen receptor natural killer (CAR-NK) cell therapy, with fludarabine and cytarabine in patients with acute myeloid leukemia. Blood 142, 2097 (2023).
Google Scholar
Dhakal, B. et al. Interim phase I clinical data of FT576 as monotherapy and in combination with daratumumab in subjects with relapsed/refractory multiple myeloma. Blood 140, 4586–4587 (2022).
Google Scholar
Yang, N. et al. CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia. J. Transl. Med. 22, 274 (2024).
Google Scholar
Muftuoglu, M. et al. Correlative data from an ongoing Phase 1, multicenter study of senti-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf CAR NK cell therapy for Acute Myeloid Leukemia (AML), is consistent with its clinical activity and unique logic gated mechanism of action. Blood 146, 5921 (2025).
Google Scholar
Burger, M. C. et al. Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma. Neuro Oncol. 25, 2058–2071 (2023).
Google Scholar
Seery, T. E. et al. Association of lymphopenia rescue and CA19-9 levels with overall survival following IL-15 superagonist N-803 and PD-L1 t-haNK chemo-immunotherapy for 3rd line or greater metastatic pancreatic cancer. J. Clin. Oncol. 43, 2542 (2025).
Google Scholar
Xiao, L. et al. Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients. Mol. Ther. 27, 1114–1125 (2019).
Google Scholar
Bachanova, V. et al. Safety and efficacy of FT522, a first-in-class, multi-antigen targeted, off-the-shelf, iPSC-derived CD19 CAR NK cell therapy with alloimmune defense receptor (ADR) in relapsed/refractory B-cell lymphoma. Blood 144, 6543 (2024).
Google Scholar
Ying, H. et al. AccuBaseTM (ceBE), a second-generation high-fidelity base editor, can proficiently modify genes in a human primary NK cells with minimizing off-target effect. Cancer Res. 84, 1328 (2024).
Google Scholar
Rafei, H. et al. Targeting T-cell lymphoma using CD70-directed cord blood-derived CAR-NK cells. Blood 142, 4811 (2023).
Google Scholar
Rafei, H. et al. CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells. Nature 643, 1076–1086 (2025).
Google Scholar
Daher, M. et al. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood 137, 624–636 (2021).
Google Scholar
Myers, J. A. & Miller, J. S. Exploring the NK cell platform for cancer immunotherapy. Nat. Rev. Clin. Oncol. 18, 85–100 (2021).
Google Scholar
Christofides, A. et al. The complex role of tumor-infiltrating macrophages. Nat. Immunol. 23, 1148–1156 (2022).
Google Scholar
Li, N. et al. A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy. Mol. Cancer 23, 117 (2024).
Google Scholar
Mantovani, A., Allavena, P., Marchesi, F. & Garlanda, C. Macrophages as tools and targets in cancer therapy. Nat. Rev. Drug Discov. 21, 799–820 (2022).
Google Scholar
Klichinsky, M. et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol. 38, 947–953 (2020).
Google Scholar
Villanueva, M. T. Macrophages get a CAR. Nat. Rev. Drug Discov. 19, 308 (2020).
Google Scholar
Underhill, D. M. & Goodridge, H. S. The many faces of ITAMs. Trends Immunol. 28, 66–73 (2007).
Google Scholar
Dooling, L. J. et al. Cooperative phagocytosis of solid tumours by macrophages triggers durable anti-tumour responses. Nat. Biomed. Eng. 7, 1081–1096 (2023).
Google Scholar
Huo, Y. et al. M1 polarization enhances the antitumor activity of chimeric antigen receptor macrophages in solid tumors. J. Transl. Med. 21, 225 (2023).
Google Scholar
Vitale, I. et al. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 30, 36–50 (2019).
Google Scholar
Casazza, A. et al. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell 24, 695–709 (2013).
Google Scholar
Toole, B. P. Emmprin (CD147), a cell surface regulator of matrix metalloproteinase production and function. Curr. Top. Dev. Biol. 54, 371–389 (2003).
Google Scholar
Pan, K. et al. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J. Exp. Clin. Cancer Res. 41, 119 (2022).
Google Scholar
Wang, M., Qin, Z., Bian, X. W. & Shi, Y. Harnessing chimeric antigen receptor macrophages against solid tumors. Cancer Commun. 45, 1344–1366 (2025).
Google Scholar
Andreesen, R. et al. Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy. Cancer Res. 50, 7450–7456 (1990).
Google Scholar
Zheng, H. et al. Chimeric antigen receptor macrophages targeting c-MET(CAR-M-c-MET) inhibit pancreatic cancer progression and improve cytotoxic chemotherapeutic efficacy. Mol. Cancer 23, 270 (2024).
Google Scholar
Wang, S. et al. CAR-macrophage: an extensive immune enhancer to fight cancer. EBioMedicine 76, 103873 (2022).
Google Scholar
Lei, A. et al. A second-generation M1-polarized CAR macrophage with antitumor efficacy. Nat. Immunol. 25, 102–116 (2024).
Google Scholar
Shen, J. et al. Activating innate immune responses repolarizes hPSC-derived CAR macrophages to improve anti-tumor activity. Cell. Stem Cell. 31, 1003–1019.e1009 (2024).
Google Scholar
Kang, M. et al. Nanocomplex-mediated in vivo programming to chimeric antigen receptor-M1 macrophages for cancer therapy. Adv. Mater. 33, e2103258 (2021).
Google Scholar
Xiao, Y., Zhu, T., Chen, Z. & Huang, X. Lung metastasis and recurrence is mitigated by CAR macrophages, in-situ-generated from mRNA delivered by small extracellular vesicles. Nat. Commun. 16, 7166 (2025).
Google Scholar
Gu, K. et al. Intraperitoneal programming of tailored CAR macrophages via mRNA lipid nanoparticle to boost cancer immunotherapy. Nat. Commun. 17, 941 (2025).
Google Scholar
Jing, W. et al. An in situ engineered chimeric IL-2 receptor potentiates the tumoricidal activity of proinflammatory CAR macrophages in renal cell carcinoma. Nat. Cancer 6, 838–853 (2025).
Google Scholar
Ginhoux, F. & Jung, S. Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat. Rev. Immunol. 14, 392–404 (2014).
Google Scholar
Zhang, L. et al. Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions. J. Hematol. Oncol. 13, 153 (2020).
Google Scholar
Reiss, K. A. et al. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nat. Med. 31, 1171–1182 (2025).
Google Scholar
Annunziata, C. M. et al. Feasibility and preliminary safety and efficacy of first-in-human intraperitoneal delivery of MCY-M11, anti-human-mesothelin CAR mRNA transfected into peripheral blood mononuclear cells, for ovarian cancer and malignant peritoneal mesothelioma. J. Clin. Oncol. 38, 3014 (2020).
Google Scholar
Chen, S. et al. CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentation. Nat. Commun. 16, 4069 (2025).
Google Scholar
Galluzzi, L. et al. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat. Rev. Clin. Oncol. 17, 725–741 (2020).
Google Scholar
Chen, S. et al. Macrophages in immunoregulation and therapeutics. Signal Transduct. Target. Ther. 8, 207 (2023).
Google Scholar
Jayasinghe, R. G. et al. Single-cell transcriptomic profiling reveals diversity in human iNKT cells across hematologic tissues. Cell Rep. 44, 115587 (2025).
Google Scholar
Bendelac, A., Savage, P. B. & Teyton, L. The biology of NKT cells. Annu. Rev. Immunol. 25, 297–336 (2007).
Google Scholar
Kawano, T. et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278, 1626–1629 (1997).
Google Scholar
Vivier, E. et al. Targeting natural killer cells and natural killer T cells in cancer. Nat. Rev. Immunol. 12, 239–252 (2012).
Google Scholar
Terabe, M. & Berzofsky, J. A. NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis. Trends Immunol. 28, 491–496 (2007).
Google Scholar
Godfrey, D. I. et al. NKT cells: what’s in a name? Nat. Rev. Immunol. 4, 231–237 (2004).
Google Scholar
Lantz, O. & Bendelac, A. An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans. J. Exp. Med. 180, 1097–1106 (1994).
Google Scholar
Gumperz, J. E., Miyake, S., Yamamura, T. & Brenner, M. B. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med. 195, 625–636 (2002).
Google Scholar
Coquet, J. M. et al. Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population. Proc. Natl. Acad. Sci. USA 105, 11287–11292 (2008).
Google Scholar
Cardell, S. et al. CD1-restricted CD4+ T cells in major histocompatibility complex class II-deficient mice. J. Exp. Med. 182, 993–1004 (1995).
Google Scholar
Renukaradhya, G. J. et al. Type I NKT cells protect (and type II NKT cells suppress) the host’s innate antitumor immune response to a B-cell lymphoma. Blood 111, 5637–5645 (2008).
Google Scholar
Metelitsa, L. S. et al. Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J. Exp. Med. 199, 1213–1221 (2004).
Google Scholar
Gorini, F. et al. Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis. Blood 129, 3440–3451 (2017).
Google Scholar
Tang, R. et al. Deciphering the prognostic implications of the components and signatures in the immune microenvironment of pancreatic ductal adenocarcinoma. Front. Immunol. 12, 648917 (2021).
Google Scholar
Tachibana, T. et al. Increased intratumor Valpha24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin. Cancer Res. 11, 7322–7327 (2005).
Google Scholar
Kawano, T. et al. Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. Cancer Res. 59, 5102–5105 (1999).
Google Scholar
Kuylenstierna, C. et al. NKG2D performs two functions in invariant NKT cells: direct TCR-independent activation of NK-like cytolysis and co-stimulation of activation by CD1d. Eur. J. Immunol. 41, 1913–1923 (2011).
Google Scholar
Fujii, S. et al. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198, 267–279 (2003).
Google Scholar
Chang, D. H. et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 108, 618–621 (2006).
Google Scholar
Song, L. et al. Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J. Clin. Invest. 119, 1524–1536 (2009).
Google Scholar
De Santo, C. et al. Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J. Clin. Invest. 118, 4036–4048 (2008).
Google Scholar
Fujii, S., Shimizu, K., Kronenberg, M. & Steinman, R. M. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat. Immunol. 3, 867–874 (2002).
Google Scholar
Keller, C. W., Freigang, S. & Lünemann, J. D. Reciprocal crosstalk between dendritic cells and natural killer T cells: mechanisms and therapeutic potential. Front. Immunol. 8, 570 (2017).
Google Scholar
Ishikawa, A. et al. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res. 11, 1910–1917 (2005).
Google Scholar
Toyoda, T. et al. Phase II study of α-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer. J. Immunother. Cancer 8, e000316 (2020).
Google Scholar
Kunii, N. et al. Combination therapy of in vitro-expanded natural killer T cells and α-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci. 100, 1092–1098 (2009).
Google Scholar
Exley, M. A. et al. Adoptive transfer of invariant NKT cells as immunotherapy for advanced melanoma: a phase I clinical trial. Clin. Cancer Res. 23, 3510–3519 (2017).
Google Scholar
Xu, Q. et al. Utilization of invariant natural killer T cells for gastric cancer treatment. Future Oncol. 14, 2053–2066 (2018).
Google Scholar
Hadfield, M. J. et al. Overcoming resistance to programmed cell death protein 1 (PD-1) blockade with allogeneic invariant natural killer T-cells (iNKT). Oncogene 43, 758–762 (2024).
Google Scholar
Heczey, A. et al. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood 124, 2824–2833 (2014).
Google Scholar
Zhou, X. et al. CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms. Nat. Cancer 5, 1607–1621 (2024).
Google Scholar
Aoki, T., Motohashi, S. & Koseki, H. Regeneration of invariant natural killer T (iNKT) cells: application of iPSC technology for iNKT cell-targeted tumor immunotherapy. Inflamm. Regen. 43, 27 (2023).
Google Scholar
Rotolo, A. et al. Enhanced anti-lymphoma activity of CAR19-iNKT cells underpinned by dual CD19 and CD1d targeting. Cancer Cell 34, 596–610.e511 (2018).
Google Scholar
Zhu, Y. et al. Development of hematopoietic stem cell-engineered invariant natural killer T cell therapy for cancer. Cell. Stem Cell. 25, 542–557.e549 (2019).
Google Scholar
Li, Y. R. et al. Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy. Mol. Ther. 32, 1849–1874 (2024).
Google Scholar
Li, Y. R. et al. Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method. Nat. Biotechnol. 43, 329–344 (2025).
Google Scholar
Heczey, A. et al. Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. Nat. Med. 26, 1686–1690 (2020).
Google Scholar
Li, Y. R. et al. Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity. J. Hematol. Oncol. 18, 86 (2025).
Google Scholar
Li, Y. R. et al. Multimodal targeting of metastatic renal cell carcinoma via CD70-directed allogeneic CAR-NKT cells. Cell Rep. Med. 6, 102321 (2025).
Google Scholar
Li, Y.-R. et al. Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies. Nat. Commun. 16, 1248 (2025).
Google Scholar
Fu, S. et al. Impaired lipid biosynthesis hinders anti-tumor efficacy of intratumoral iNKT cells. Nat. Commun. 11, 438 (2020).
Google Scholar
Dockry, É et al. Epigenetic induction of CD1d expression primes lung cancer cells for killing by invariant natural killer T cells. Oncoimmunology 7, e1428156 (2018).
Google Scholar
Sainz, V. et al. α-Galactosylceramide and peptide-based nano-vaccine synergistically induced a strong tumor suppressive effect in melanoma. Acta Biomater. 76, 193–207 (2018).
Google Scholar
Gálvez, N. M. S. et al. Type I natural killer T cells as key regulators of the immune response to infectious diseases. Clin. Microbiol. Rev. 34, e00232-20 (2021).
Google Scholar
Stirnemann, K. et al. Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice. J. Clin. Invest. 118, 994–1005 (2008).
Google Scholar
Yamada, D. et al. Efficient production of functional human NKT cells from induced pluripotent stem cells – reprogramming of human Vα24(+)iNKT cells. Bio Protoc. 7, e2277 (2017).
Google Scholar
Gebremeskel, S. et al. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis. J. Immunother. Cancer 9, e002096 (2021).
Google Scholar
Randolph, G. J. Dendritic cells: the first step. J. Exp. Med. 218, e20202077 (2021).
Google Scholar
Cabeza-Cabrerizo, M. et al. Dendritic cells revisited. Annu. Rev. Immunol. 39, 131–166 (2021).
Google Scholar
Heras-Murillo, I. et al. Dendritic cells as orchestrators of anticancer immunity and immunotherapy. Nat. Rev. Clin. Oncol. 21, 257–277 (2024).
Google Scholar
Clayton, G., Toffoli, E. C., de Gruijl, T. D. & van Kooyk, Y. Dendritic cell immunotherapy advances for solid tumors: vaccination and modulation. Cell Rep. Med. 6, 102412 (2025).
Google Scholar
Wang, Y. et al. Dendritic cell biology and its role in tumor immunotherapy. J. Hematol. Oncol. 13, 107 (2020).
Google Scholar
Wculek, S. K. et al. Dendritic cells in cancer immunology and immunotherapy. Nat. Rev. Immunol. 20, 7–24 (2020).
Google Scholar
Rossjohn, J. et al. T cell antigen receptor recognition of antigen-presenting molecules. Annu. Rev. Immunol. 33, 169–200 (2015).
Google Scholar
Zhou, Z. et al. Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. Science 368, eaaz7548 (2020).
Google Scholar
Halim, T. Y. et al. Group 2 innate lymphoid cells license dendritic cells to potentiate memory TH2 cell responses. Nat. Immunol. 17, 57–64 (2016).
Google Scholar
Steinman, R. M. & Cohn, Z. A. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med. 137, 1142–1162 (1973).
Google Scholar
Banchereau, J. & Steinman, R. M. Dendritic cells and the control of immunity. Nature 392, 245–252 (1998).
Google Scholar
Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422 (2010).
Google Scholar
Maslak, P. G. et al. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Adv. 2, 224–234 (2018).
Google Scholar
Zauderer, M. G. et al. A randomized phase II trial of adjuvant galinpepimut-S, WT-1 analogue peptide vaccine, after multimodality therapy for patients with malignant pleural mesothelioma. Clin. Cancer Res. 23, 7483–7489 (2017).
Google Scholar
Bol, K. F. et al. Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial. Nat. Commun. 15, 1632 (2024).
Google Scholar
Liau, L. M. et al. Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial. JAMA Oncol. 9, 112–121 (2023).
Google Scholar
Koido, S. et al. Dendritic cells pulsed with multifunctional Wilms’ tumor 1 (WT1) peptides combined with multiagent chemotherapy modulate the tumor microenvironment and enable conversion surgery in pancreatic cancer. J. Immunother. Cancer 12, e009765 (2024).
Google Scholar
Chen, Y. et al. Safety and feasibility of personalized neoantigen DC vaccines in postoperative esophagus squamous cell carcinoma: a Phase 1b trial. Cancer Res. 84, 4108 (2024).
Google Scholar
Lin, C.-L. S. et al. Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res. 62, 6952–6958 (2002).
Google Scholar
Stevens, D. et al. Dendritic cell-based immunotherapy in lung cancer. Front. Immunol. 11, 620374 (2020).
Google Scholar
Ascic, E. et al. In vivo dendritic cell reprogramming for cancer immunotherapy. Science 386, eadn9083 (2024).
Google Scholar
Wang, J. et al. Targeting vaccines to dendritic cells by mimicking the processing and presentation of antigens in xenotransplant rejection. Nat. Biomed. Eng. 9, 201–214 (2025).
Google Scholar
Kim, J. et al. Dual adjuvant-loaded peptide antigen self-assembly potentiates dendritic cell-mediated tumor immunotherapy. Adv. Sci. 11, e2403663 (2024).
Google Scholar
Qi, S. et al. Supramolecular lipid nanoparticles based on host-guest recognition: a new generation delivery system of mRNA vaccines for cancer immunotherapy. Adv. Mater. 36, e2311574 (2024).
Google Scholar
Zhang, C. et al. mRNA-based vaccination drives in vivo dendritic cell reprogramming and selective cytotoxic T lymphocyte modulation for enhanced antitumor immunity. ACS Nano. 19, 38267–38283 (2025).
Google Scholar
Dan, J. et al. Oncolytic virus M1 functions as a bifunctional checkpoint inhibitor to enhance the antitumor activity of DC vaccine. Cell Rep. Med. 4, 101229 (2023).
Google Scholar
Falcone, N. et al. Peptide hydrogels as immunomaterials and their use in cancer immunotherapy delivery. Adv. Health. Mater. 12, e2301096 (2023).
Google Scholar
Dong, H. et al. Biomaterials facilitating dendritic cell-mediated cancer immunotherapy. Adv. Sci. 10, e2301339 (2023).
Google Scholar
Han, X. et al. Biomaterial-assisted biotherapy: a brief review of biomaterials used in drug delivery, vaccine development, gene therapy, and stem cell therapy. Bioact. Mater. 17, 29–48 (2022).
Google Scholar
Laumont, C. M. et al. Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities. Nat. Rev. Cancer 22, 414–430 (2022).
Google Scholar
Laumont, C. M. & Nelson, B. H. B cells in the tumor microenvironment: multi-faceted organizers, regulators, and effectors of anti-tumor immunity. Cancer Cell 41, 466–489 (2023).
Google Scholar
Thommen, D. S. et al. A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat. Med. 24, 994–1004 (2018).
Google Scholar
Engelhard, V. et al. B cells and cancer. Cancer Cell 39, 1293–1296 (2021).
Google Scholar
Sautès-Fridman, C., Petitprez, F., Calderaro, J. & Fridman, W. H. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19, 307–325 (2019).
Google Scholar
Hu, C. et al. Tertiary lymphoid structure-associated B cells enhance CXCL13(+)CD103(+)CD8(+) tissue-resident memory T-cell response to programmed cell death protein 1 blockade in cancer immunotherapy. Gastroenterology 166, 1069–1084 (2024).
Google Scholar
Yang, M. et al. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer. J. Immunother. Cancer 9, e001136 (2021).
Google Scholar
Ma, J. et al. A blueprint for tumor-infiltrating B cells across human cancers. Science 384, eadj4857 (2024).
Google Scholar
Chen, J. et al. Single-cell transcriptome and antigen-immunoglobin analysis reveals the diversity of B cells in non-small cell lung cancer. Genome Biol. 21, 152 (2020).
Google Scholar
Wennhold, K. et al. CD86(+) antigen-presenting B cells are increased in cancer, localize in tertiary lymphoid structures, and induce specific T-cell responses. Cancer Immunol. Res. 9, 1098–1108 (2021).
Google Scholar
Cai, X. et al. Re-analysis of single cell and spatial transcriptomics data reveals B cell landscape in gastric cancer microenvironment and its potential crosstalk with tumor cells for clinical prognosis. J. Transl. Med. 22, 807 (2024).
Google Scholar
Meylan, M. et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity 55, 527–541.e525 (2022).
Google Scholar
Biswas, S. et al. IgA transcytosis and antigen recognition govern ovarian cancer immunity. Nature 591, 464–470 (2021).
Google Scholar
Li, Z. et al. Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death. Cell 187, 624–641.e623 (2024).
Google Scholar
Wouters, M. C. A. & Nelson, B. H. Prognostic significance of tumor-infiltrating B cells and plasma cells in human cancer. Clin. Cancer Res. 24, 6125–6135 (2018).
Google Scholar
Hladíková, K. et al. Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8(+) T cells. J. Immunother. Cancer 7, 261 (2019).
Google Scholar
Cabrita, R. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577, 561–565 (2020).
Google Scholar
Petitprez, F. et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 577, 556–560 (2020).
Google Scholar
Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549–555 (2020).
Google Scholar
Gottlin, E. B. et al. The Association of Intratumoral Germinal Centers with early-stage non-small cell lung cancer. J. Thorac. Oncol. 6, 1687–1690 (2011).
Google Scholar
Cole, A. C. et al. Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity. Cancer Cell 43, 1697–1713.e1698 (2025).
Google Scholar
Xu, Y. et al. Tumor-infiltrated activated B cells suppress liver metastasis of colorectal cancers. Cell Rep. 40, 111295 (2022).
Google Scholar
Sorrentino, R. et al. B cells contribute to the antitumor activity of CpG-oligodeoxynucleotide in a mouse model of metastatic lung carcinoma. Am. J. Respir. Crit. Care Med. 183, 1369–1379 (2011).
Google Scholar
Li, Q. et al. Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin. Cancer Res. 17, 4987–4995 (2011).
Google Scholar
Hollern, D. P. et al. B cells and T follicular helper cells mediate response to checkpoint inhibitors in high mutation burden mouse models of breast cancer. Cell 179, 1191–1206.e1121 (2019).
Google Scholar
Jo, A. et al. CTLA-4 inhibition facilitates follicular T and B cell interaction and the production of tumor-specific antibodies. Int. J. Cancer 152, 1964–1976 (2023).
Google Scholar
Yofe, I. et al. Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling. Nat. Cancer 3, 1336–1350 (2022).
Google Scholar
van Dijk, N. et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat. Med. 26, 1839–1844 (2020).
Google Scholar
Martins, F. et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 16, 563–580 (2019).
Google Scholar
Maldonado, L. et al. Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. Sci. Transl. Med. 6, 221ra213 (2014).
Google Scholar
Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894–1905 (2020).
Google Scholar
Rini, B. I. et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 393, 2404–2415 (2019).
Google Scholar
Weinstein, A. M. et al. Tbet and IL-36γ cooperate in therapeutic DC-mediated promotion of ectopic lymphoid organogenesis in the tumor microenvironment. Oncoimmunology 6, e1322238 (2017).
Google Scholar
Cupedo, T., Jansen, W., Kraal, G. & Mebius, R. E. Induction of secondary and tertiary lymphoid structures in the skin. Immunity 21, 655–667 (2004).
Google Scholar
Suematsu, S. & Watanabe, T. Generation of a synthetic lymphoid tissue–like organoid in mice. Nat. Biotechnol. 22, 1539–1545 (2004).
Google Scholar
Lee, J. M. et al. Phase I trial of intratumoral injection of CCL21 gene-modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8(+) T-cell infiltration. Clin. Cancer Res. 23, 4556–4568 (2017).
Google Scholar
Mathieu, M. et al. Inflammation enhances the vaccination potential of CD40-activated B cells in mice. Eur. J. Immunol. 47, 269–279 (2017).
Google Scholar
Lee-Chang, C. et al. Activation of 4-1BBL+ B cells with CD40 agonism and IFNγ elicits potent immunity against glioblastoma. J. Exp. Med. 218, e20200913 (2021).
Google Scholar
Romain, G. et al. Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells. Blood 124, 3241–3249 (2014).
Google Scholar
Bodogai, M. et al. Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L. Cancer Res. 73, 2127–2138 (2013).
Google Scholar
Somasundaram, R. et al. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nat. Commun. 8, 607 (2017).
Google Scholar
Das, S. & Bar-Sagi, D. BTK signaling drives CD1d(hi)CD5(+) regulatory B-cell differentiation to promote pancreatic carcinogenesis. Oncogene 38, 3316–3324 (2019).
Google Scholar
Gunderson, A. J. et al. Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer. Cancer Discov. 6, 270–285 (2016).
Google Scholar
Li, S. et al. STING-induced regulatory B cells compromise NK function in cancer immunity. Nature 610, 373–380 (2022).
Google Scholar
Mirlekar, B. et al. Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity. Cell Rep. Med. 3, 100744 (2022).
Google Scholar
Hoang, D. M. et al. Stem cell-based therapy for human diseases. Signal Transduct. Target. Ther. 7, 272 (2022).
Google Scholar
Ma, S., Meng, Z., Chen, R. & Guan, K. L. The Hippo pathway: biology and pathophysiology. Annu. Rev. Biochem. 88, 577–604 (2019).
Google Scholar
Sugiyama, T., Kohara, H., Noda, M. & Nagasawa, T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 25, 977–988 (2006).
Google Scholar
de Araújo Farias, V., Carrillo-Gálvez, A. B., Martín, F. & Anderson, P. TGF-β and mesenchymal stromal cells in regenerative medicine, autoimmunity and cancer. Cytokine Growth Factor Rev. 43, 25–37 (2018).
Google Scholar
Sun, L. et al. Tumor-associated mesenchymal stem/stromal cells in tumor microenvironment and carcinogenesis. Exp. Hematol. Oncol. 14, 97 (2025).
Google Scholar
Lozito, T. P., Jackson, W. M., Nesti, L. J. & Tuan, R. S. Human mesenchymal stem cells generate a distinct pericellular zone of MMP activities via binding of MMPs and secretion of high levels of TIMPs. Matrix Biol. 34, 132–143 (2014).
Google Scholar
Li, N. et al. Potent prophylactic cancer vaccines harnessing surface antigens shared by tumour cells and induced pluripotent stem cells. Nat. Biomed. Eng. 9, 215–233 (2025).
Google Scholar
Ramalho-Santos, M. & Willenbring, H. On the origin of the term “stem cell”. Cell. Stem Cell. 1, 35–38 (2007).
Google Scholar
Jansen, J. The first successful allogeneic bone-marrow transplant: Georges Mathé. Transfus. Med Rev. 19, 246–248 (2005).
Google Scholar
Yin, J. Q., Zhu, J. & Ankrum, J. A. Manufacturing of primed mesenchymal stromal cells for therapy. Nat. Biomed. Eng. 3, 90–104 (2019).
Google Scholar
Huang, R. et al. Mesenchymal stem cells for prophylaxis of chronic graft-vs-host disease after haploidentical hematopoietic stem cell transplant: an open-label randomized clinical trial. JAMA Oncol. 10, 220–226 (2024).
Google Scholar
Yao, H. et al. Sequential infusion of mesenchymal stem cell for graft-versus-host disease prevention in haploidentical hematopoietic stem cell transplantation: an open-label, multicenter, randomized controlled clinical trial. J. Clin. Oncol. 43, 1997–2006 (2025).
Google Scholar
Lv, C. et al. Pluripotent stem cell-derived CD19-CAR iT cells effectively eradicate B-cell lymphoma in vivo. Cell Mol. Immunol. 18, 773–775 (2021).
Google Scholar
Wang, C., Liu, J. & Li, W. ‘Off the shelf’ immunotherapies: Generation and application of pluripotent stem cell-derived immune cells. Cell Prolif. 56, e13425 (2023).
Google Scholar
Gardner, R. et al. Lentiviral transduction of Notch ligand expanded cord blood HSC’s to express a CD19-specific CAR generates NK and myeloid progeny with antitumor activity. Blood 122, 900 (2013).
Google Scholar
Zhang, H. et al. New avenues for cancer immunotherapy: cell-mediated drug delivery systems. J. Control Release 375, 712–732 (2024).
Google Scholar
Shi, Y. et al. Engineered mesenchymal stem/stromal cells against cancer. Cell Death Dis. 16, 113 (2025).
Google Scholar
Grisendi, G. et al. Combining gemcitabine and MSC delivering soluble TRAIL to target pancreatic adenocarcinoma and its stroma. Cell Rep. Med. 5, 101685 (2024).
Google Scholar
Ghasemi Darestani, N. et al. Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment. Cell Commun. Signal. 21, 43 (2023).
Google Scholar
Lai, Y. H. et al. Stem cell-nanomedicine system as a theranostic bio-gadolinium agent for targeted neutron capture cancer therapy. Nat. Commun. 14, 285 (2023).
Google Scholar
Layek, B., Sadhukha, T., Panyam, J. & Prabha, S. Nano-engineered mesenchymal stem cells increase therapeutic efficacy of anticancer drug through true active tumor targeting. Mol. Cancer Ther. 17, 1196–1206 (2018).
Google Scholar
Chen, Y. et al. Recent advances in CAR-MSCs: the new engine of cellular immunotherapy evolution. J. Hematol. Oncol. 18, 92 (2025).
Google Scholar
Sirpilla, O. et al. Mesenchymal stromal cells with chimaeric antigen receptors for enhanced immunosuppression. Nat. Biomed. Eng. 8, 443–460 (2024).
Google Scholar
Yan, L., Li, J. & Zhang, C. The role of MSCs and CAR-MSCs in cellular immunotherapy. Cell Commun. Signal. 21, 187 (2023).
Google Scholar
Sirpilla, O. et al. Chimeric antigen receptor engineering of mesenchymal stromal cells (CAR-MSC) enhance immunosuppression and outcomes in graft versus host disease (GvHD) preclinical models. Blood 140, 1579–1580 (2022).
Google Scholar
Niu, Z. et al. CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies. Front. Immunol. 15, 1385571 (2024).
Google Scholar
Golinelli, G. et al. Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors. Cancer Gene Ther. 27, 558–570 (2020).
Google Scholar
Golinelli, G. et al. Anti-GD2 CAR MSCs against metastatic Ewing’s sarcoma. Transl. Oncol. 15, 101240 (2022).
Google Scholar
Aliperta, R. et al. Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts. Blood Cancer J. 5, e348 (2015).
Google Scholar
Tang, S. et al. NKG2D-CAR-targeted iPSC-derived MSCs efficiently target solid tumors expressing NKG2D ligand. iScience 28, 112343 (2025).
Google Scholar
Deuse, T. & Schrepfer, S. Progress and challenges in developing allogeneic cell therapies. Cell. Stem Cell. 32, 513–528 (2025).
Google Scholar
Sharkis, S. J., Jones, R. J., Civin, C. & Jang, Y. Y. Pluripotent stem cell-based cancer therapy: promise and challenges. Sci. Transl. Med. 4, 127ps9 (2012).
Google Scholar
Zhang, Z. et al. Advances in nanomedicine for targeting cancer stem cells and overcoming therapeutic resistance. ACS Nano. 19, 30720–30757 (2025).
Google Scholar
Brudno, J. N. & Kochenderfer, J. N. Current understanding and management of CAR T cell-associated toxicities. Nat. Rev. Clin. Oncol. 21, 501–521 (2024).
Google Scholar
Sesques, P. et al. Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma. J. Hematol. Oncol. 17, 61 (2024).
Google Scholar
Li, Y. R. et al. Managing allorejection in off-the-shelf CAR-engineered cell therapies. Mol. Ther. 33, 2368–2390 (2025).
Google Scholar
Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat. Rev. Clin. Oncol. 17, 147–167 (2020).
Google Scholar
Mulvey, A., Trueb, L., Coukos, G. & Arber, C. Novel strategies to manage CAR-T cell toxicity. Nat. Rev. Drug Discov. 24, 379–397 (2025).
Google Scholar
Lane, I. C. et al. Genetic retargeting of E3 ligases to enhance CAR T cell therapy. Cell Chem. Biol. 31, 338–348.e335 (2024).
Google Scholar
Adams, E. L. et al. Small-molecule control of CAR T cells. Nat. Rev. Chem. 9, 809–825 (2025).
Google Scholar
Huang, Z. et al. Engineering light-controllable CAR T cells for cancer immunotherapy. Sci. Adv. 6, eaay9209 (2020).
Google Scholar
Jan, M. et al. Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide. Sci. Transl. Med. 13, eabb6295 (2021).
Google Scholar
Li, X. et al. Suppression of cytokine release syndrome during CAR-T-cell therapy via a subcutaneously injected interleukin-6-adsorbing hydrogel. Nat. Biomed. Eng. 7, 1129–1141 (2023).
Google Scholar
Bollard, C. M. & Heslop, H. E. T cells for viral infections after allogeneic hematopoietic stem cell transplant. Blood 127, 3331–3340 (2016).
Google Scholar
Schweitzer, L. & Muranski, P. Virus-specific T cell therapy to treat refractory viral infections in solid organ transplant recipients. Am. J. Transplant. 24, 1558–1566 (2024).
Google Scholar
Tang, R. et al. A chimeric conjugate of antibody and programmable DNA nanoassembly smartly activates T cells for precise cancer cell targeting. Angew. Chem. Int. Ed. Engl. 61, e202205902 (2022).
Google Scholar
Srivastava, S. et al. Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting. Cancer Cell 35, 489–503.e488 (2019).
Google Scholar
Dagher, O. K. & Posey, A. D. Jr Forks in the road for CAR T and CAR NK cell cancer therapies. Nat. Immunol. 24, 1994–2007 (2023).
Google Scholar
Chan, J. D. et al. Cellular networks controlling T cell persistence in adoptive cell therapy. Nat. Rev. Immunol. 21, 769–784 (2021).
Google Scholar
Levy, O. et al. Shattering barriers toward clinically meaningful MSC therapies. Sci. Adv. 6, eaba6884 (2020).
Google Scholar
Miller, J. S. et al. Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy. Biol. Blood Marrow Transplant. 20, 1252–1257 (2014).
Google Scholar
Sabado, R. L., Balan, S. & Bhardwaj, N. Dendritic cell-based immunotherapy. Cell Res. 27, 74–95 (2017).
Google Scholar
Wu, Z. et al. Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy. Cell 188, 6317–6334.e6321 (2025).
Google Scholar
Shields, C. W. T. et al. Cellular backpacks for macrophage immunotherapy. Sci. Adv. 6, eaaz6579 (2020).
Google Scholar
Li, S. et al. Amplifying antigen-induced cellular responses with proximity labelling. Nature 647, 506–516 (2025).
Google Scholar
Ai, K. et al. Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies. J. Hematol. Oncol. 17, 105 (2024).
Google Scholar
Du, B. et al. CAR-T therapy in solid tumors. Cancer Cell 43, 665–679 (2025).
Google Scholar
Wang, P. et al. Chimeric antigen receptor with novel intracellular modules improves antitumor performance of T cells. Signal Transduct. Target. Ther. 10, 20 (2025).
Google Scholar
Papa, S. et al. Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study. J. Immunother. Cancer 11, e007162 (2023).
Google Scholar
Vitanza, N. A. et al. Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial. Nat. Med. 31, 861–868 (2025).
Google Scholar
Aarntzen, E. H. et al. Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells. Clin. Cancer Res. 19, 1525–1533 (2013).
Google Scholar
DeFilipp, Z. et al. RGI-2001 for the prophylaxis of acute graft-versus-host disease after allogeneic HCT. Blood 146, 2037–2046 (2025).
Google Scholar
He, M. et al. Noninvasive in vivo tracking of SPIONs-labeled CLDN18.2-targeted CAR-T cells in gastric cancer via magnetic particle imaging. Transl. Res. 283, 3–12 (2025).
Google Scholar
Liu, J. Q. et al. Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy. J. Control Release 345, 306–313 (2022).
Google Scholar
Li, Y. et al. In situ engineering of mRNA-CAR T cells using spleen-targeted ionizable lipid nanoparticles to eliminate cancer cells. Nano Today 59, 102518 (2024).
Google Scholar
Depil, S. et al. ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nat. Rev. Drug Discov. 19, 185–199 (2020).
Google Scholar
Yip, A. & Webster, R. M. The market for chimeric antigen receptor T cell therapies. Nat. Rev. Drug Discov. 17, 161–162 (2018).
Google Scholar
Murray, I. R. et al. International expert consensus on a cell therapy communication tool: DOSES. J. Bone Jt. Surg. Am. 101, 904–911 (2019).
Google Scholar
Liu, X., Kuang, L., Wu, L. & Li, Y. High throughput sequencing in oncology: from tumor characterization to novel therapies. Holist. Integr. Oncol. 5, 16 (2026).
Google Scholar
Polak, R., Zhang, E. T. & Kuo, C. J. Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment. Nat. Rev. Cancer 24, 523–539 (2024).
Google Scholar
Zhang, C. et al. Phase I escalating-dose trial of CAR-T therapy targeting CEA(+) metastatic colorectal cancers. Mol. Ther. 25, 1248–1258 (2017).
Google Scholar
Zhang, Y. et al. Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients. J. Cancer Res. Clin. Oncol. 147, 3725–3734 (2021).
Google Scholar
Ahmed, N. et al. HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol. 3, 1094–1101 (2017).
Google Scholar
Rohaan, M. W. et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N. Engl. J. Med. 387, 2113–2125 (2022).
Google Scholar
Creelan, B. C. et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat. Med. 27, 1410–1418 (2021).
Google Scholar
Sarnaik, A. A. et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J. Clin. Oncol. 39, 2656–2666 (2021).
Google Scholar
Heczey, A. et al. Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat. Med. 29, 1379–1388 (2023).
Google Scholar
